EFPIA Shares Industry View of EMA Regulatory Framework - a podcast by Unknown

Scientific advancements in pharmaceutical R&D are simultaneously benefiting patients and challenging industry and regulatory frameworks throughout Europe. “The pharmaceutical R&D of today is driven by groundbreaking innovation which has the potential to transform patient treatments and improve patient outcomes, as we move more and more from treating symptoms to really treating the underlying cause of diseases,” explains Dr. Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). “Developing this new generation of treatments raises new and challenging questions of our regulatory system, underlying the need for evolution to adapt to such advanced technologies.”

Further episodes of DIA: Driving Insights to Action

Further podcasts by Unknown

Website of Unknown